Andalucía BIORegión

Producto

Hibor®

Hibor® (Bemiparin) is a low molecular weight heparin indicated for preventing and treating thromboembolic disease (TED), both in surgical and medical patients, and for the intense and long-term treatment of patients who have suffered a TED process.

Hibor® (Bemiparin) is also indicated for preventing coagulation in the extracorporeal circuit during haemodialysis.

Hibor® (Bemiparin) has as its main feature the fact that it can be administered 2 hours before or 6 hours after surgery. Its post-surgery dosage has the advantage of reducing the risk of spinal hematoma and contributes to reducing hospital costs, as patients can be admitted on the day of surgery.

Hibor® (Bemiparin) has consolidated its position in the market for anti-thrombosis drugs as the second most-sold LMWH in Spain, with a market share of 27% at the end of December 2008 (ISM, January 2009)

Hibor® (Bemiparin) has a significant international presence. The product has been approved in 35 countries in 4 continents, has been approved and is pending marketing in another 6 countries, and is in the approval process in a further 18 countries.